Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.
Yao Y, Ng JF, Park WD, Samur M, Morelli E, Encinas Mayoral J, Chyra Z, Xu Y, Derebail S, Epstein C, Nabet B, Chesi M, Gray NS, Young RA, Kwiatkowski N, Mitsiades C, Anderson KC, Lin CY, Munshi NC, Fulciniti M. Yao Y, et al. Among authors: anderson kc. Blood. 2023 Jun 8;141(23):2841-2852. doi: 10.1182/blood.2022018885. Blood. 2023. PMID: 36877894 Free PMC article.
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma.
Du T, Song Y, Ray A, Wan X, Yao Y, Samur MK, Shen C, Penailillo J, Sewastianik T, Tai YT, Fulciniti M, Munshi NC, Wu H, Carrasco RD, Chauhan D, Anderson KC. Du T, et al. Among authors: anderson kc. Blood. 2023 May 25;141(21):2599-2614. doi: 10.1182/blood.2022017897. Blood. 2023. PMID: 36630605 Free PMC article.
Monoallelic deletion of BCMA is a frequent feature in multiple myeloma.
Samur MK, Aktas Samur A, Corre J, Lannes R, Shah P, Anderson K, Avet-Loiseau H, Munshi N. Samur MK, et al. Blood Adv. 2023 Nov 14;7(21):6599-6603. doi: 10.1182/bloodadvances.2023010025. Blood Adv. 2023. PMID: 37611163 Free PMC article. No abstract available.
Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.
Liu J, Yan W, Fan H, Xu J, Li L, Du C, Mao X, Yan Y, Xu Y, Sui W, Deng S, Yi S, Anderson KC, Qiu L, Zou D, An G. Liu J, et al. Among authors: anderson kc. Cancer Res Commun. 2023 Sep 6;3(9):1770-1780. doi: 10.1158/2767-9764.CRC-23-0185. eCollection 2023 Sep. Cancer Res Commun. 2023. PMID: 37680953 Free PMC article.
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival.
Prabhala R, Pierceall WE, Samur M, Potluri LB, Hong K, Peluso T, Talluri S, Wang A, Katiki A, Vangala SD, Buonopane M, Bade V, Seah H, Krogman A, Derebail S, Fulciniti M, Lazo SB, Richardson P, Anderson K, Corre J, Avet-Loiseau H, Thakurta A, Munshi N. Prabhala R, et al. Front Oncol. 2023 Dec 4;13:1271807. doi: 10.3389/fonc.2023.1271807. eCollection 2023. Front Oncol. 2023. PMID: 38111533 Free PMC article.
Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells.
Edri A, Ben-Haim N, Hailu A, Brycman N, Berhani-Zipori O, Rifman J, Cohen S, Yackoubov D, Rosenberg M, Simantov R, Teru H, Kurata K, Anderson KC, Hendel A, Pato A, Geffen Y. Edri A, et al. Among authors: anderson kc. Int J Mol Sci. 2023 Dec 7;24(24):17231. doi: 10.3390/ijms242417231. Int J Mol Sci. 2023. PMID: 38139060 Free PMC article.
Shrinking the divide: improving myeloma CART access.
Nooka AK, Hartley-Brown MA, Anderson KC, Lonial S. Nooka AK, et al. Among authors: anderson kc. Blood Adv. 2024 Jan 9;8(1):248-250. doi: 10.1182/bloodadvances.2023011659. Blood Adv. 2024. PMID: 38194242 Free PMC article. No abstract available.
1,221 results